We elucidate The underlying mechanisms of bidirectional cardiorenal interaction, focusing on The sympathetic nerve driving disruption of The local renin-angiotensin system (RAS). A rat model of N ω-nitro-L-arginine methyl ester (L-NAME; a nitric oxide synthase inhibitor) administration was used to induce damage in The heart and kidney, similar to cardiorenal syndrome. L-NAME induced sympathetic nerve-RAS overactivity and cardiorenal injury accompanied by local RAS elevations. These were suppressed by bilateral renal denervation, but not by hydralazine treatment, despite The blood pressure being kept The same between The two groups. Although L-NAME induced angiotensinogen (AGT) protein augmentation in both organs, AGT mRNA decreased in The kidney and increased in The heart in a contradictory manner. Immunostaining for AGT suggested that renal denervation suppressed AGT onsite generation from activated resident macrophages of The heart and circulating AGT excretion from glomeruli of The kidney. We also examined rats treated with L-NAME plus unilateral denervation to confirm direct sympathetic regulation of intrarenal RAS. The levels of urinary AGT and renal angiotensin II content and The degrees of renal injury from denervated kidneys were less than those from contralateral innervated kidneys within The same rats. Thus, renal denervation has blood pressure-independent beneficial effects associated with local RAS inhibition.
All Science Journal Classification (ASJC) codes